UNSPSC 51432306: Olmesartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C29H30N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M97XTV3HD, chemically known as 1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1h-tetrazol-5-yl) (1,1-biphenyl)-4-yl)methyl)- but generally known as olmesartan, which bears US NIH Compound Identifier 158781. European Medicines Agency schedules Olmesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20707.

UNSPSC 51432306 Olmesartan, a Commodity code, represents pharmaceutical products procured by state and local governments for emergency medical services, health benefit programs, and cooperative purchasing coalitions. State and local buyers are soliciting olmesartan and related cardiovascular medications through emergency services procurement (Tampa Fire Rescue), state health and human services agencies evaluating direct-to-manufacturer pharmacy programs (Texas HHS), and multistate cooperative purchasing alliances supplying generic pharmaceuticals to member jurisdictions (Minnesota). The scope of work spans individual medication procurement for pre-hospital and emergency care, exploratory vendor engagement for alternative pharmacy benefit delivery models, and bulk generic pharmaceutical contracting through wholesaler-mediated supply chains. Issuing bodies include city fire departments, state health commissions, and multistate cooperative purchasing organizations that aggregate demand across dozens of participating state agencies, counties, municipalities, and special districts.

Recent activity shows geographic concentration in Florida, Texas, and the Upper Midwest through the Minnesota cooperative. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, soliciting Advanced Life Support Medications (including labetalol, epinephrine, adenosine, and diltiazem) with a due date of April 8, 2026 and an estimated contract value of $40,000 under SLBE sheltered-market terms offering a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 in late March 2026 (due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit managers and wholesalers. The Minnesota Department of Administration issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products through MMCAP with a due date of March 26, 2026; awarded vendors supply through three authorized wholesalers effective July 1, 2026, with a two-year initial term and performance penalties ranging from $200 to $1,500 per violation. The olmesartan code shows limited direct solicitation activity; most recent opportunities tag broader pharmaceutical families or alternative delivery mechanisms rather than olmesartan as a specific line item.